Dr. John Corboy on the risk of relapse/new MRI lesions in people who stop disease modifying therapy and observational studies such as DISCOMS and DOTMS. He also discussed extended interval dosing with b-cell depleters. www.neurologylive.com/view/discont...
The professor of neurology at the University of Colorado discussed evidence from DISCOMS and other trials on disease-modifying therapy discontinuation in older, stable patients with multiple sclerosis...
